Peficitinib体外对淋巴细胞活化的药理作用:JAK抑制剂治疗系统性硬化的潜在可能
本研究为体外药理学研究,评估Peficitinib对RA和SSc患者外周血单个核细胞及SSc皮肤标本中STAT磷酸化的抑制作用。结果显示RA和SSc患者T细胞和单核细胞自发STAT1或STAT3磷酸化高于健康人,SSc皮损中几乎均见磷酸化STAT3阳性细胞,Peficitinib可抑制多种细胞因子诱导的STAT磷酸化及细胞因子/趋化因子产生,效力与tofacitinib和baricitinib相当。提示JAK/STAT通路在SSc和RA中持续活化,JAK抑制剂可能为SSc的新治疗选择。
要点
- RA和SSc患者外周T细胞和单核细胞自发STAT1或STAT3磷酸化高于健康人。
- SSc皮损中几乎均见磷酸化STAT3阳性细胞,不依赖亚型或患者特征。
- Peficitinib抑制STAT磷酸化及细胞因子/趋化因子产生,效力与tofacitinib和baricitinib相当。
核心结论
- JAK/STAT通路在SSc和RA中持续活化,JAK抑制剂可能为SSc提供新的治疗选择。
研究设计与样本
- 体外研究,检测RA或SSc患者及健康者外周血单个核细胞和19例SSc患者皮肤标本的STAT磷酸化。
- 比较Peficitinib、tofacitinib和baricitinib对STAT磷酸化及细胞因子/趋化因子产生的体外抑制作用。
主要发现
- RA和SSc患者外周T细胞和单核细胞自发STAT1或STAT3磷酸化高于健康人。
- SSc皮肤切片中几乎全部病例可见磷酸化STAT3阳性细胞,与疾病亚型或患者特征无关。
- 磷酸化STAT1阳性细胞仅见于未治疗、病程短的弥漫性SSc患者标本。
- Peficitinib抑制多种细胞因子诱导的STAT磷酸化,效力与tofacitinib和baricitinib相当。
- Peficitinib抑制外周血单个核细胞和皮肤成纤维细胞的细胞因子及趋化因子产生。
临床怎么用
- 提示JAK抑制剂可能用于SSc治疗,但需进一步临床研究验证。
局限性
- 为体外研究,尚不能直接推断临床疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Peficitinib, a novel Janus kinase (JAK) inhibitor, demonstrated promising results in treating RA in phase 3 clinical trials. This in vitro study was undertaken to characterize the pharmacological properties of peficitinib and investigate the involvement of JAK and signal transducer and activator of transcription (STAT) pathways in the pathological processes of SSc, which is also an autoimmune disease. METHODS: Phosphorylation levels of STAT molecules were assessed in peripheral blood mononuclear cells collected from patients with RA or SSc and healthy subjects, and in skin specimens obtained from 19 patients with SSc. In vitro inhibition of STAT phosphorylation and cytokine/chemokine production by peficitinib, tofacitinib and baricitinib were also characterized. RESULTS: Higher spontaneous STAT1 or STAT3 phosphorylation was observed in peripheral T-cells and monocytes from patients with RA and SSc compared with healthy subjects. In skin sections from patients with SSc, phosphorylated STAT3-positive cells were found in almost all cases, irrespective of disease subtype or patient characteristics. Conversely, phosphorylated STAT1-positive cells were observed only in samples from untreated patients with diffuse disease of short duration. Peficitinib inhibited STAT phosphorylation induced by various cytokines, with comparable efficacy to tofacitinib and baricitinib. Peficitinib also suppressed cytokine and chemokine production by peripheral blood mononuclear cells and skin fibroblasts. CONCLUSION: Our results suggest that JAK/STAT pathways are constitutively activated in SSc and RA, and that the JAK inhibitor may represent a novel therapeutic option for SSc.
引用
- Kitanaga Y, Imamura E, Nakahara Y, et al. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology (Oxford). 2020. PMID: 31764973. doi:10.1093/rheumatology/kez526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。